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A randomized double-blind trial with a 7-valent pneumococcal conjugate vaccine was conducted in The
Netherlands among 383 children, aged 1 to 7 years, with a history of recurrent acute otitis media. No effect of
vaccination on the pneumococcal colonization rate was found. However, a shift in serotype distribution was
clearly observed (R. Veenhoven et al., Lancet 361:2189–2195, 2003). We investigated the molecular epidemi-
ology of 921 pneumococcal isolates retrieved from both the pneumococcal vaccine (PV) and control vaccine
(CV) groups during the vaccination study. Within individuals a high turnover rate of pneumococcal restriction
fragment end labeling genotypes, which was unaffected by vaccination, was observed. Comparison of the genetic
structures before and after completion of the vaccination scheme revealed that, despite a shift in serotypes,
there was clustering of 70% of the pneumococcal populations. The remaining isolates (30%) were equally
observed in the PV and CV groups. In addition, the degree of genetic clustering was unaffected by vaccination.
However, within the population genetic structure, nonvaccine serotype clusters with the serotypes 11, 15, and
23B became predominant over vaccine-type clusters after vaccination. Finally, overall pneumococcal resistance
was low (14%), and, albeit not significant, a reduction in pneumococcal resistance as a result of pneumococcal
vaccination was observed. Molecular surveillance of colonization in Dutch children shows no effect of pneu-
mococcal conjugate vaccination on the degree of genetic clustering and the genetic structure of the pneumo-
coccal population. However, within the genetic pneumococcal population structure, a clear shift toward
nonvaccine serotype clusters was observed.
Streptococcus pneumoniae is worldwide one of the major
bacterial causes of invasive disease and respiratory tract infec-
tions in children. Risk groups for pneumococcal infections are
young children, elderly, and immune-deficient patients. Despite
adequate antibiotic treatment, morbidity and mortality due to
pneumococcal disease remain high (5). Moreover, the increasing
(multi)drug resistance among pneumococcal isolates hampers ad-
equate treatment (6, 11, 21, 30). New pneumococcal conjugate
vaccines have been shown to be effective against invasive diseases
in young children (3). Furthermore, a protective effect against
respiratory tract infections such as (recurrent) otitis media has
been observed (3, 15). Thus far, the 7-valent pneumococcal con-
jugate vaccine Prevnar (Wyeth) has been approved by the U.S.
Food and Drug Administration and the European Committee on
Proprietary Medicinal Products and is recommended by the U.S.
Advisory Committee on Immunization Practices for the preven-
tion of invasive diseases in children under 2 years of age. Recom-
mendations are also made for older children at increased risk for
invasive disease, such as those with human immunodeficiency
virus infection and asplenia and those with increased risk for
pneumococcal mucosal disease, such as children with recurrent
acute otitis media (1). We recently studied the effect of a 7-valent
pneumococcal conjugate vaccine followed by a 23-valent polysac-
charide vaccine in children aged 1 to 7 years with a history of
recurrent acute otitis media (32). Clinically, no protective effect of
the pneumococcal vaccines on recurrence of acute otitis media
was found. At the nasopharyngeal level, however, a significant
reduction of colonization with vaccine-type pneumococci was
found after vaccination, whereas a simultaneous increase in col-
onization with nonvaccine serotypes was observed (32).
In this study, we investigated the molecular epidemiological
dynamics and resistance profiles of the pneumococcal isolates
collected from both children in the pneumococcal vaccine
(PV) and the hepatitis control vaccine (CV) groups in order to
obtain insight into the effect of conjugate vaccination on the
genetic pneumococcal population structure.
MATERIALS AND METHODS
Bacterial isolates. In total, 383 children, aged 1 to 7 years, suffering from
recurrent acute otitis media, were enrolled in this double-blind randomized
vaccination trial in the period April 1998 to December 2001 (32). One hundred
ninety children received a 7-valent pneumococcal conjugate vaccine, either once
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for children 24 months of age and older (Prevnar; Wyeth Lederle) or twice for
children 12 to 24 months of age, followed by a 23-valent pneumococcal polysac-
charide vaccine after 6 months for all children (Pneumune; Wyeth Lederle). The
193 control children received, depending on the age, hepatitis B vaccine (En-
gerix-B; SmithKline Beecham) three times or hepatitis A vaccine (Havrix junior;
SmithKline Beecham) twice. Nasopharyngeal cultures were performed at study
entry; just before booster vaccination at 7 months; and at 14, 20, and 26 months.
An additional nasopharyngeal sample was obtained at the first acute otitis media
event after full vaccination. Pneumococcal carriage was observed in around 50%
of all children. This carriage rate was maintained in both study groups in the
26-month follow-up period. Thus, no influence on overall colonization was ob-
served during the study. Instead a decline in vaccine serotype carriage was
observed in the PV group whereas the nonvaccine serotype carriage increased
(32). Nine hundred twenty-one isolates (95%) from 353 out of 383 patients
participating in this study were available for further analysis by genotyping and
susceptibility testing.
Bacteriological procedures. Isolation and identification of the S. pneumoniae
isolates were performed by standard methods as described previously (32). Sus-
ceptibility testing was performed by the agar dilution method (25). Resistance
was defined by the breakpoint concentrations for the respective antibiotics as
defined by the NCCLS (26). Multidrug resistance was defined as resistance to
three or more classes of antimicrobial agents.
Serotyping. Pneumococci were serotyped by the method of capsular swelling
(Quellung reaction) with commercially available antisera (Statens Serum Insti-
tute, Copenhagen, Denmark).
RFEL typing. Pneumococcal strain typing by restriction fragment end labeling
(RFEL) was done as described by van Steenbergen et al. (31) and adapted by
Hermans et al. (19). Briefly, purified pneumococcal DNA was digested by the
restriction enzyme EcoRI. The DNA restriction fragments were end labeled at
72°C with [-32P]dATP by using DNA polymerase (Goldstar; Eurogentec, Se-
raing, Belgium). After the radiolabeled fragments were denatured and separated
electrophoretically on a 6% polyacrylamide sequencing gel containing 8 M urea,
the gel was transferred onto filter paper, vacuum dried (HBI, Saddlebrook,
N.Y.), and exposed for variable times at room temperature to ECL hyperfilm
(Amersham Laboratories, Amersham, United Kingdom).
Computer-assisted analysis of DNA band patterns. RFEL autoradiographs
were converted to images (Image Master DTS; Pharmacia Biotech, Uppsala,
Sweden) and analyzed by computer (Windows Gelcompar software, version 4;
Applied Math., Kortrijk, Belgium). DNA fragments were analyzed as described
previously (27). For evaluation of the genetic relatedness of the isolates we used
the following definitions: (i) isolates of a particular RFEL type are 100% iden-
tical by RFEL analysis; (ii) an RFEL cluster represents a group of RFEL types
that differ in only one band (approximately 95% genetic relatedness). A RFEL
genotype that is found only once in the collection is defined as a unique RFEL
type. A RFEL type that is found twice or more, or that is more than 95% related
to another RFEL type, is defined as a clustering genotype.
MLST. The RFEL genotypes of 34 isolates representing different serotypes
were investigated by multilocus sequence typing (MLST) analysis. Within the 23
largest clusters, representing 27 RFEL genotypes, the most prevalent serotypes
were analyzed. For this purpose, a fully automated method for MLST was used
as described previously (20). The MLST types were compared with the global
PMEN database (http://spneumoniae.mlst.net/pmen/pmen.asp).
Data analysis. P values for differences were calculated with the chi-square test
using Prism, version 3.00 for Windows (GraphPad Software, San Diego, Calif.).
RESULTS
Nine hundred twenty-one pneumococcal isolates from naso-
pharyngeal samples of 351 children participating in the study
were available for molecular analysis by RFEL. In total, 450 of
these 921 pneumococcal isolates were isolated from children in
the PV group, whereas 471 isolates were isolated from children
in the CV group. Of the 921 isolates, 180 isolates were isolated
at the start of the study (time [T]  0 months; day of [first]
conjugate vaccination); 176 isolates were retrieved at 7 months
(day of booster vaccination); and 186, 163, and 119 isolates
were isolated after completion of the vaccination scheme at 14,
20, and 26 months of study duration, respectively (Table 1).
The remaining 97 isolates were retrieved at the first acute otitis
media events after full vaccination (7 months). The serotype
distribution of all pneumococcal isolates collected during this
study was discussed previously (32). In summary, the contribu-
tion of vaccine serotype pneumococci to colonization gradually
declined from 46% at study entry to 26% at the end of the
study compared to the CV group, in which the contribution of
the conjugate vaccine serotypes remained approximately 50%
whereas the total pneumococcal carriage rate remained unaf-
fected.
All 921 isolates were characterized by RFEL. We identified
275 different RFEL genotypes representing 1 to 49 isolates per
genotype, with an average of 3.35 isolates per genotype. Anal-
ysis of the per-patient follow-up revealed a high turnover rate
of pneumococcal RFEL genotypes; persistent carriage for at
most three consecutive samples (recurrence twice after a 6- to
7-month interval) was found in only 54 out of the 351 children
(Table 2). No statistical difference in the rate of persistent
carriage between the pneumococcal vaccine group and the
control group children was found (15 versus 16%; P 0.67). In
both groups, the majority of the persistent isolates (60%) had
nonvaccine serotypes. On three occasions, persistence of a
specific genotype was accompanied by a switch in serotype. In
one case, colonization with an isolate having one particular
genotype which is closely related to the MLST type displaying
serotype 15 was followed 6 months later by colonization with
an isolate having a second genotype of serotype 19A. Another
6 months later the initial genotype with a capsular switch to
serotype 19A was identified. In the second case a switch from
serotype 14 to serotype 8 within the same genotype was ob-
served after a 6-month interval. The third case represented a
capsular switch from serotype 6A to serotype 19F, observed
after a 6-month interval.
We analyzed the genetic relatedness of the pneumococcal
isolates retrieved at the start of the study and 14 months after
the initial vaccination from both study groups. The 180 pneu-
mococci isolated at the start of the study displayed 93 RFEL
genotypes, representing 52 unique RFEL genotypes and 30
clusters (128 isolates), with an average cluster size of 4.3. The
186 isolates isolated 14 months after the start of the study
displayed 105 RFEL genotypes, representing 54 unique RFEL
genotypes and 29 clusters (132 isolates), with an average clus-
ter size of 4.6. Close homology (95% genetic relatedness)
among 70% of the isolates was found at both time points (T 
0 months and T  14 months). The remaining RFEL geno-
types equally represented strains from either PV or CV chil-
dren (49 and 51%, respectively). The four most predominant
TABLE 1. Pneumococcal isolates with regard to study group and
study phase
Phase
Total
no. of
isolates
PV group CV group
No. of
isolates
% Vaccine-
type strains
No. of
isolates
% Vaccine-
type strains
All 921 451 470
0 mo 180 96 46 84 58
7 mo 176 81 41 95 46
14 mo 186 84 26 102 40
20 mo 163 81 25 82 49
26 mo 119 64 26 55 54
First AOMa 97 45 24 52 44
a AOM, acute otitis media.
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TABLE 2. Pneumococcal colonization dynamics of the 351 children according to study and age groupa
Group, age range,
and patient no.
Type of pneumococci carried at:
Group, age range,
and patient no.
Type of pneumococci carried at:
Mo
0
Mo
7
Mo
14
Mo
20
Mo
26
First
AOMb
event
Mo
0
Mo
7
Mo
14
Mo
20
Mo
26
First
AOMb
Event
PV
12–24 mo
1 1 1 1 0
2 1 1 1 1 1
3 1 1
4 1 1
5 1 1 1 1
6 1 1 1
7 1 0
8 0 0 0 0 1
9 1
10 1
11 0 1 0
12 0 0
13 1 0 1
14 1 1 0
15 1 1 0
16 1
17 0 0 1
18 0
19 1 0 1 1
20 0 1
21 0 1
22 0 0 1 0
23 0 1 1
24 0 0
25 1 1 0
26 0 1
27 1 1
28 1 1 1 1
29 1 0 1 1
30 0 0 1
31 0 1
32 1
33 1 1 1 1
34 0 0 1 0 1
35 0 1
36 0 0 0
37 0 1 1 1 1
38 0 0 1 1 1 1
39 1 1 1
40 1
41 1 1 1
42 1
43 1
44 0
45 0 0 1 1
46 1 1 1
47 1
48 1 1
49 1 1
50 1 1
51 1 0 1 0
52 0 0
53 1 0 1 0
54 0
55 1 1 1 1
56 0 1
57 0 1
58 1 1 1
59 0
60 0 1 1
61 1 0
62 1 1
63 1 1
64 0
65 1
66 1 1 1
67 0 1 1
68 0 0
69 0
70 1
71 0 1
72 0 1 1 1
73 1 0
74 1 0
2–7 yr
75 0 1 0 0 1
76 1 1
77 0
78 0 1
79 1
80 0 0 0 0 1
81 1 0 1
82 1 0 1
83 1 0
84 1 1 1
85 1 0
86 1 1 1 1
87 1 0 1
88 1 1 1 1 1
89 1 1 1
90 1
91 1 1
92 0
93 0 1 1 1
94 1
95 1 1 1
96 1
97 1 1
98 0
99 1 1 1 1
100 0 1 1 0
101 0 0 0
102 1 0 1 1
103 1 0
104 0
105 0 0 0
106 1 1 1
107 1 0
108 0 0
109 1 1
110 1 1 1
111 0 1
112 1 1
113 0 1 1 1 0
114 1
115 1 0
116 1 1 1
117 1 0 0 0
118 1 1 1 1
119 1 1 1
120 1 1 0
121 1 1 1
122 0 0
123 1 1 1 1 1
124 1 0 1 1 1
125 0 1
126 0 0 0 1
127 1 1
128 0 1 1 1 1
Continued on facing page
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TABLE 2—Continued
Group, age range,
and patient no.
Type of pneumococci carried at:
Group, age range,
and patient no.
Type of pneumococci carried at:
Mo
0
Mo
7
Mo
14
Mo
20
Mo
26
First
AOMb
event
Mo
0
Mo
7
Mo
14
Mo
20
Mo
26
First
AOMb
event
129 1 1
130 0 1 0 1 1
131 1
132 1 1 0 0
133 1 1
134 1 1 1 0 1
135 0 1
136 1 1 1
137 1 1 0 0
138 0 1
139 0 1
140 1 1 1
141 1 1 0
142 1 1 1 1 1
143 1 1 1 0
144 1 0
145 1 1 1
146 1 1
147 0 1 1
148 0 0
149 0 1
150 1 1 1
151 1
152 0 1
153 0 1
154 1 0
155 1
156 1 0
157 1 1
158 1
159 1 1 1
160 1 0 0 1
161 1 1 1
162 0 0 1 0 1
163 1 0 0
164 0 1
165 0
166 1 0 1
167 0 0
168 1 1
169 1 0
170 1
171 1 0
CV
12–24 mo
1 0 0 0 0
2 0 0 0 1
3 0
4 1 1 1
5 0 0 0 1
6 0 0
7 0 1 0
8 0 1 1 0
9 1 0
10 1 0
11 1 1
12 1 0 0 0
13 1 1 0 0
14 0
15 0 0
16 0 1 0 1 1
17 0 1 0
18 1 1 0
19 1 1 1 1 0
20 1 0
21 0 1 1
22 0
23 0 0
24 1 0 1
25 1
26 1 1
27 1 0
28 1 1 1 0 1 1
29 1 0 1 0/1
30 0 1 1
31 1 0 0
32 1 0 1 0 1
33 0
34 1 1
35 0
36 0 0
37 0 1 0
38 0 0 1 0 0 1
39 1
40 0 0 0/1
41 0 1 0 1 0
42 1 0 0 1
43 1 1 0 1
44 0 0 0
45 0 1 0
46 0 0 1 0 0 0
47 0 0 0 0 0
48 1 1 0 0
49 1
50 0 0
51 0 1
52 1
53 0
54 0 1 0
55 1 0 0/1
56 0 0 0 0 0
57 0
58 0
59 1
60 0 1
61 0 0 1
62 0
63 1 0 0 0
64 1
65 0 1
66 1 0 1
67 0
68 0 1
69 1 1
70 1 1 1
71 0 0 0
72 1 1
73 0 0 0 0
74 1
75 1 0
76 1 0
2–7 yr
77 0 1 0 1
78 1
79 0
80 1
81 1
82 1 0 0
83 1 0
84 0 0 0 1 1
85 0 0 1
86 1 0
Continued on following page
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clusters at the start of the study were cluster I (7.8% of all
isolates; serotypes 6A and 6B), cluster II (7.3%; serotype 14),
cluster III (4.5%; serotype 23F), and cluster IV (4.5%; sero-
type 9V). These clusters were still predominant 14 months
after vaccination, though slightly reduced in size (4.8, 4.3, 4.3,
and 2.2%, respectively) and mainly observed in CV group
children (Fig. 1). In addition, five minor clusters observed in
the initial phase of the study, cluster A (2.8% of all isolates;
serotype 11), cluster B (1.1%; serotype 11), cluster C (2.8%;
serotype 15), cluster D (2.8%; serotype 16), and cluster E
(1.7%; serotype 23B), became predominant clusters 14 months
after vaccination with prevalences of 4.8, 4.3, 4.3, 5.4, and
3.8%, respectively. The first two clusters, which had 85% ho-
mology, were predominantly present in PV children (89 and
63%, respectively) (Fig. 1).
We investigated 34 isolates representing different serotypes
by MLST analysis. Within the 23 largest clusters, representing
27 RFEL genotypes, the most prevalent serotypes were ana-
lyzed (Fig. 2). We found no PMEN clones in our collection of
pneumococci. However, we observed close homology with sev-
eral of the PMEN clones, i.e., three single-locus variants of the
PMEN clones France 9V-3 (ST 162), Tennessee 23F-4 (ST
439), and Portugal 19F-21 (ST 1045) and one double-locus
variant of the PMEN clone Hungary 19A-16 (ST 176). In
TABLE 2—Continued
Group, age range,
and patient no.
Type of pneumococci carried at:
Group, age range,
and patient no.
Type of pneumococci carried at:
Mo 0 Mo 7 Mo 14 Mo 20 Mo 26
First
AOMb
event
Mo 0 Mo 7 Mo 14 Mo 20 Mo 26
First
AOMb
event
87 1 0 1 1
88 0 1
89 1 0 0
90 1 0 1
91 1 1 1
92 1 0
93 1 1 0
94 1
95 1 1 0 1
96 0 1 0 1
97 0 1 1
98 1 1 1
99 0 1 1 1
100 1 0
101 0
102 0 0 0 0
103 1
104 1 0 1 0
105 1
106 1 0 1
107 0 1/0
108 1 1 0/1 0/0
109 1 1
110 0 0
111 0
112 1
113 0
114 0 1
115 0
116 0 0 0 0
117 1 0 1
118 1 0
119 0 1 1 0
120 1
121 0
122 1 1
123 0 0
124 0 0 1 1 1
125 0 1 0 1
126 0 1 0
127 1 0
128 1 0 0 0
129 1 1 1
130 1 1
131 0 1 1
132 1 1 1 1
a Boldface indicates persistent carriage. 1, vaccine-type pneumococci; 0, nonvaccine-type pneumococci. Values separated by shills indicate the results for two different
isolates cultured.
b AOM, acute otitis media.
133 0 1 1 1
134 0 0 0
135 0 0 0
136 0 1
137 1 0 0
138 0
139 1 1 1 1
140 0 1 1 1 1 0
141 0 1 1
142 1 1 0 0
143 0
144 1 1 1 1
145 0
146 0 0 1 1
147 1 1
148 1 0 1
149 0
150 1 1 1
151 0
152 0
153 0 1 0
154 1 1
155 0 1
156 1 1
157 1
158 0 1 1 0
159 0 1 0 1
160 0
161 1 0
162 1 1 0
163 0
164 0 1
165 0 1 1
166 0 0 0 1
167 1 1 1
168 0 1
169 1 1
170 1
171 1 1 1
172 1
173 0 0 1
174 1 0
175 1
176 1 0
177 0
178 1 1 1
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FIG. 1. Population RFEL structure of the 180 and 186 pneumococcal isolates retrieved before vaccination (T  0 months) and after
pneumococcal conjugate vaccination (T  14 months), respectively. Levels of genetic relatedness are depicted as percentages. The serotypes and
numbers of isolates per genotype are shown in bars for the two periods separately. The contributions of PV children and CV children are shown
in grey and black, respectively. I to IV, predominant clusters at the initial phase of the study; A to E, emerging clusters after conjugate vaccination.
Clusters consisting of two or more RFEL genotypes are in parentheses. x, clusters of one RFEL genotype.
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addition, we observed two new MLST genotypes (ST 1181 and
ST 1182). In general, the observed homology by RFEL geno-
typing was confirmed by MLST, except for RFEL genotype
028, for which RFEL genotyping was demonstrated to be less
discriminatory than MLST analysis (Fig. 2).
We determined the MICs of penicillin, cotrimoxazole, tet-
racycline, erythromycin, rifampin, vancomycin, and ciprofloxa-
cin for 919 isolates. Resistance to at least one antibiotic was
found for 128 pneumococcal isolates (14%). High-level resis-
tance to penicillin, cotrimoxazole, tetracycline, erythromycin,
and ciprofloxacin was found in 2 (0.2%), 37 (4.0%), 28 (3.0%),
29 (3.2%), and 2 (0.2%) isolates, respectively. Furthermore,
intermediate resistance to penicillin and cotrimoxazole was
found in 8 (0.9%) and 61 (6.6%) isolates, respectively. Inter-
mediate resistance to tetracycline, erythromycin, and cefo-
taxime was seen only occasionally (Table 3). No cases of re-
sistance to rifampin and vancomycin were identified. In Table
4, the resistance profiles and the associated rates, serotypes,
and numbers of RFEL genotypes are listed. In total, 21 differ-
ent resistance profiles were observed. We observed (interme-
diate) resistance to a single drug in 99 isolates (10.7% of all
isolates), dual resistance in 17 isolates (1.8%), and multidrug
resistance (resistance to three or more antibiotics) in 12 iso-
lates (1.3%).
To evaluate the effect of vaccination on pneumococcal re-
sistance, we compared resistance rates before full vaccination
(samples at study entry and at the 7-month point) and after full
vaccination (samples at 14, 20, and 26 months). In the PV
children resistance declined from 17.5% before full vaccination
to 11.8% after full vaccination, whereas in the CV children
resistance was stable (14.5 and 14.3% before and after full
vaccination, respectively). This difference did not reach statis-
tical significance. We also evaluated the serotype distribution
among the resistant isolates. Fifty-seven percent of all resistant
isolates displayed vaccine serotypes. In addition, 10 out of the
12 multidrug-resistant isolates (83%) were vaccine serotype
isolates, whereas the remaining two isolates displayed the
cross-reactive serotype 6A.
DISCUSSION
Between 1998 and 2002 a large randomized, double-blind
vaccination trial with a 7-valent pneumococcal conjugate vac-
cine followed by a 23-valent polysaccharide vaccine was per-
formed with 383 children, aged 1 to 7 years, with a history of
recurrent acute otitis media. Surprisingly, no beneficial effect
on the frequency of acute otitis media after pneumococcal
vaccination or on the overall colonization rate of S. pneu-
moniae was observed. However, a shift of vaccine-type pneu-
mococci to nonvaccine-type pneumococci was observed among
nasopharyngeal colonization isolates. Emerging nonconjugate
vaccine serotypes were serotypes 11, 15, and 16 (32). We ques-
tioned whether this shift occurred within specific RFEL geno-
FIG. 2. RFEL dendrogram of the 34 MLST sequence types observed within the 29 largest RFEL clusters.
TABLE 3. Antibiotic resistance rates for the
S. pneumoniae collection
Drug No. of resistantstrains
% Of
total
No. of
intermediately
resistant strains
% Of
total
Penicillin 2 0.2 8 0.9
Cotrimoxazole 37 4.0 61 6.6
Tetracycline 28 3.0 5 0.5
Erythromycin 29 3.2 1 0.1
Ciprofloxacin 2 0.2 0
Cefotaxime 0 2 0.2
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types or whether replacement with genetically different strains
took place. If the latter was true, we wondered if these different
RFEL genotypes were equally capable of horizontal dissemi-
nation and whether they represented comparable antibiotic
resistance profiles.
Therefore, we analyzed the 921 pneumococcal isolates re-
trieved from 351 of the 383 participating children. We ob-
served 275 different RFEL genotypes, representing 106 genetic
clusters and 75 unique RFEL genotypes. Analyzing the per-
patient follow-up revealed few episodes of persistent carriage.
This implies that pneumococcal colonization is a dynamical
process with a high turnover rate of colonizing strains. No
effect of vaccination on the limited rate of persistent strains
was found. This was to be expected, because the majority of the
persistent strains in both the PV and CV groups represented
nonvaccine serotypes.
Remarkably, in three cases of persistent carriage, a serotype
switch was observed. However, one could argue whether con-
secutive colonization with the serotype 15 and serotype 19A
variants of a strain closely related to MLST 199 suggests the
recruitment of a second isolate with identical genotype rather
than a capsular switch. However, in contrast to the situation
observed in many countries, including the United States, this
genotype is not very common in The Netherlands (3%), and a
19A serotype variant had not been observed before. Although
a strain switch cannot be excluded, we believe that these data
are suggestive of a capsular switch. So far, this phenomenon, in
vivo, has been reported only twice, by Barnes et al. (2) and
Sluijter et al. (27). Indirect proof for a capsular switch was
previously shown by other investigators, who demonstrated the
true recombinational exchanges at the capsular locus (7–9, 24).
One might argue that our observations are events enhanced by
conjugate vaccination due to the induction of a selective im-
munological pressure. Indeed, the serotype 15-to-19A switch
was observed in a PV child, but no conjugate vaccine-type
pneumococci were involved. The two additional cases (sero-
type 6A-to-19F and 14-to-8 switches) were observed in CV
children. Although our data support the theory that serotype
switching is a natural process which can be observed occasion-
ally within an individual, a large number of data will be re-
quired to study the impact of conjugate vaccination on this
process.
Comparison of the genetic structures of the pneumococci
isolated at study entry and at 14 months after pneumococcal
conjugate vaccination showed 70% homology among the pneu-
mococcal isolates at the two time points. The nonoverlapping
isolates were equally distributed among PV and CV children.
Furthermore, initially predominant clusters displaying vaccine
serotypes had been partially replaced by nonvaccine serotype
clusters after vaccination, which displayed a similar capability
to spread horizontally. Though replacement by nonvaccine se-
rotypes as a result of increasing age has been proven to occur
(12), we observed this shift significantly more often in children
who received the pneumococcal vaccines, indicating that this
process is enhanced by vaccination.
Our most predominant clusters represented multiple vaccine
and nonvaccine serotypes. Since the observed genetic homol-
ogy was confirmed by MLST analysis, our data suggest that a
large number of recombinational events at the capsular loci
have occurred within these clusters. This is in line with previ-
ous data from the United States and Latin America, where the
major (resistant) clones also show multiple serotypes as a re-
sult of capsular serotype switch (9, 10, 16, 22, 29). Wolf et al.
(33) have shown that these events occur even more often in
TABLE 4. S. pneumoniae antibiotic resistance profiles, profile rates, and numbers of genotypes and their serotype distribution
Resistance profilea No. ofstrains (%)
No. of
genotypes Serotype(s)
Co(I) 53 (5.7) 29 3/7/8/10/11/12/14/18C/18F/6A/6B/9A/9V/19A/19F/23F/31/33D/NTb
Co 25 (2.7) 16 6A/6B/9V/18C/21/23F/NT/34
T 7 (0.8) 6 3/19C/19F
T(I) 4 (0.4) 4 23F/18C/11/38
T(I)E 1 (0.1) 1 33
Tci 1 (0.1) 1 19F
TE 7 (0.8) 6 9N/19F
E 8 (0.9) 6 11/14/15/33
E(I) 1 (0.1) 1 23B
Co(I)E 2 (0.2) 2 6A/8
Co(I)T 1 (0.1) 1 6B
Co(I)TE 1 (0.1) 1 6B
CoT 2 (0.2) 2 23A/19F
CoTE 5 (0.5) 4 6A/6B
P(I) 1 (0.1) 1 11
P(I)CoCf(I) 1 (0.1) 1 14
P(I)Co(I)ECf(I) 1 (0.1) 1 6B
P(I)CoTE 3 (0.3) 3 19F/6B/14
PCo(I) 1 (0.1) 1 15
P(I)Co(I) 2 (0.2) 2 14/23F
PCoTE 1 (0.1) 1 6B
PE 1 (0.1) 1 6A
Total 128 (13.8)
a Co, cotrimoxazole; P, penicillin; T, tetracycline; E, erythromycin; Cf, cefotaxime; Ci, ciprofloxacin; (I), intermediate resistance.
b NT, nontypeable.
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susceptible pneumococcal clones, which is in line with our
findings.
Our data support the hypothesis that serotype replacement
observed after conjugate vaccination does not directly indicate
a shift in the genetic structure of the pneumococcal popula-
tion. Shifts toward and the predominance of nonvaccine sero-
type variants are likely to occur within genetic clusters display-
ing both vaccine and nonvaccine serotypes. However, MLST
analysis of the most predominant clusters of our collection of
pneumococcal strains showed the presence of several new ge-
notypes and the absence of PMEN homologous clones. There-
fore, this collection of strains might not be representative and
predictive for countries where multidrug-resistant clones are
predominantly present.
To evaluate whether vaccination will have an effect on the
presence of antibiotic resistance, we determined the antibiotic
resistance profiles of all 921 isolates. Susceptibility testing of
919 of the 921 pneumococcal isolates was performed for pen-
icillin, cotrimoxazole, tetracycline, erythromycin, rifampin,
vancomycin, cefotaxime, and ciprofloxacin. In agreement with
previous studies performed in The Netherlands, the overall
resistance is low (14% of the isolates) compared to that found
in other European countries (4, 13, 14, 17, 18). Penicillin re-
sistance was found rarely in our study. In contrast, we most
frequently observed resistance to cotrimoxazole, tetracycline,
and erythromycin. We compared our data with a previous
study performed in The Netherlands, where 10,489 clinical
pneumococcal isolates have been tested for drug susceptibility
(14). Compared to results from this study (reference year,
1999), we noted a higher incidence of cotrimoxazole resistance
(4.4 versus 10.6%) and a lower incidence of tetracycline resis-
tance (3.5 versus 6.6%). Both observations can be explained by
the age difference between the study groups; our study was
performed with children under 7 years of age, whereas the
surveillance study represented all age groups, including adults.
Tetracyclines, routinely given to adults, are contraindicated in
children whereas cotrimoxazole is often the first-choice treat-
ment.
In a comparison of our study population to the surveillance
study population, we found equal percentages of (intermedi-
ate) resistance to a single drug (77% of the resistant isolates),
comparable levels of dual resistance (13 and 19%, respec-
tively), and significantly higher levels of multidrug resistance (9
and 4%, respectively; P  0.01). We hypothesize that our
children might select for multidrug-resistant strains because of
higher antibiotic consumption, which is in accordance with
previous findings (23, 28).
In addition, we analyzed changes in the incidence of pneu-
mococcal resistance. In this respect, we compared levels of
resistance among the pneumococcal isolates between the ini-
tial phases of the study (before full vaccination) and the post-
vaccination phases. Although a decline in resistance from 17.5
to 11.8% was seen, this was not statistically significant. Because
of the low resistance rates, no subsidiary analysis could be
performed for the separate sample dates. Therefore, we ana-
lyzed the serotype distribution among the resistant isolates;
this analysis showed that the serotype distribution for 57% of
the resistant isolates is comparable to the overall serotype
distribution. However, all multidrug-resistant isolates had vac-
cine types or cross-reactive serotypes. Although resistance is
low among S. pneumoniae in The Netherlands, these data
imply that vaccination with the 7-valent conjugate vaccine may
reduce pneumococcal resistance in the population, particularly
multidrug resistance.
In conclusion, pneumococcal conjugate vaccination did not
induce a shift in the population-based structure of the pneu-
mococci or decrease their tendency to spread horizontally. Our
observations combined with the vaccine efficacy data of Veen-
hoven et al. (32) suggest that pneumococcal conjugate vacci-
nation is not very useful for prevention of pneumococcal col-
onization in children above 1 year of age. Moreover, we
strongly advise continuous and close monitoring of the pneu-
mococcal genetic structure in areas with a conjugate vaccina-
tion policy.
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